Stephanie M Bates
Overview
Explore the profile of Stephanie M Bates including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
254
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bates S, Evans K, Delsing L, Wong R, Cornish G, Bahjat M
Drug Discov Today
. 2024 Nov;
29(12):104239.
PMID: 39521331
The promise of curative outcomes for life-limiting diseases using cell therapies is starting to become a reality, not only for patients with end-stage cancer, but also increasingly for regenerative therapies,...
2.
Callender L, Curran M, Bates S, Mairesse M, Weigandt J, Betts C
Front Immunol
. 2020 Sep;
11:1991.
PMID: 32903476
Evidence from the global outbreak of SARS-CoV-2 has clearly demonstrated that individuals with pre-existing comorbidities are at a much greater risk of dying from COVID-19. This is of great concern...
3.
Sayers E, Peel S, Schantz A, England R, Beano M, Bates S, et al.
Mol Ther
. 2019 Aug;
27(11):1950-1962.
PMID: 31427168
Lipid nanoparticles have great potential for delivering nucleic-acid-based therapeutics, but low efficiency limits their broad clinical translation. Differences in transfection capacity between in vitro models used for nanoparticle pre-clinical testing...
4.
Saleh A, Lazaro-Ibanez E, Forsgard M, Shatnyeva O, Osteikoetxea X, Karlsson F, et al.
Nanoscale
. 2019 Mar;
11(14):6990-7001.
PMID: 30916672
Extracellular vesicles (EVs) mediate cellular communication through the transfer of active biomolecules, raising interest in using them as biological delivery vehicles for therapeutic drugs. For drug delivery applications, it is...
5.
Lamore S, Ahlberg E, Boyer S, Lamb M, Hortigon-Vinagre M, Rodriguez V, et al.
Toxicol Sci
. 2017 Apr;
158(1):213-226.
PMID: 28453775
Many drugs designed to inhibit kinases have their clinical utility limited by cardiotoxicity-related label warnings or prescribing restrictions. While this liability is widely recognized, designing safer kinase inhibitors (KI) requires...